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A b s t r a c t
Many anti-diabetic drugs with different mechanisms of action are now avail-
able for treatment of type 2 diabetes mellitus. Sulfonylureas have been ex-
tensively used for treatment of type 2 diabetes for nearly 50 years and, 
even in our times, are widely used for treatment of this devastating chronic 
illness. Here, we review some of the available data on sulfonylureas, eval-
uating their mechanism of action and their effects on glycemic control. We 
can conclude that sulfonylureas are still the most used anti-diabetic agents: 
maybe this is due to their lower cost, to the possibility of mono-dosing and 
to the presence of an association with metformin in the same tablet. How-
ever, sulfonylureas, especially the older ones, are linked to a greater prev-
alence of hypoglycemia, and cardiovascular risk; newer prolonged-release 
preparations of sulfonylureas are undoubtedly safer, mainly due to reducing 
hypoglycemia, and for this reason should be preferred.
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Introduction
Many anti-diabetic drugs with different mechanisms of action are 
now available to treat type 2 diabetes mellitus, including sulfonylureas, 
glinides, thiazolidinediones [1, 2], biguanides [3], and α-glucosidase in-
hibitors [4, 5]. Recently, incretin-related drugs, such as dipeptidyl pep-
tidase-4 (DPP-4) inhibitors [6, 7], and glucagon-like peptide-1 (GLP-1) 
receptor agonists [8, 9], have been developed. Despite the large number 
of anti-diabetic agents available, however, sulfonylureas remain the most 
widely used drugs for treating patients with type 2 diabetes [10].
Sulfonylureas were discovered in 1942, when Janbon et al. observed 
that some sulfonamides generated hypoglycemia in experimental ani-
mals. From this observation carbutamide (1-butyl-3-sulfonylurea) was 
synthesized. Carbutamide was the first sulfonylurea used to treat dia-
betes, but was subsequently withdrawn from the market because of its 
adverse effects on bone marrow.
By the 1960s several sulfonylureas became available; they are tra-
ditionally classified into 2 groups (or generations). Gliclazide, glipizide, 
glibenclamide and glimepiride are second-generation sulfonylureas, cur-
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rently used, while first-generation drugs (such as 
tolbutamide and chlorpropamide) are no longer 
used. Second-generation drugs are equally effec-
tive in lowering blood glucose concentrations, but 
there are differences in absorption, metabolism 
and dosing (Table I).
Sulfonylureas should be considered for dia-
betic patients who are not overweight or those 
for whom metformin is contraindicated or is not 
enough to achieve adequate glycemic control [11].
Mechanism of action
The main effect of sulfonylureas is the rise in 
plasma insulin concentrations; consequently they 
are effective only when residual pancreatic β-cells 
are present. The rise in plasma insulin levels occurs 
for two reasons. Firstly, there is stimulation of in-
sulin secretion by pancreatic β-cells, and secondly, 
there is a decrease in hepatic clearance of insulin. 
In particular, this second effect appears mainly 
after the increase of insulin secretion has taken 
place. In fact, in the first month of treatment, the 
levels of insulin and insulin response to glucose 
rise rapidly, resulting in lowered blood glucose. 
After this period, baseline and stimulated insulin 
levels become lower compared to those measured 
at the beginning of treatment; however, blood 
glucose values remain unchanged. The reason for 
this observation is not clear. With regard to the 
secretory activity of sulfonylureas, the mechanism 
is now known. They act by binding to the specif-
ic receptor for sulfonylureas on β-pancreatic cells, 
blocking the inflow of potassium (K+) through the 
ATP-dependent channel: the flow of K+ within the 
β-cell goes to zero, the cell membrane becomes 
depolarized, thus removing the electric screen 
which prevents the diffusion of calcium into the 
cytosol. The increased flow of calcium into β-cells 
causes the contraction of the filaments of acto-
myosin responsible for the exocytosis of insulin, 
which is therefore promptly secreted in large 
amounts (Figure 1). 
In particular, the sulfonylureas receptor (SUR1), 
a  1581-amino acid protein, has high affinity for 
Table I. Various generations of sulfonylureas 
Molecules Gen. Dose [mg] Duration of 
action* T1/2
Activity of  
metabolites 
T1/2
Elimination Structure
Tolbutamide I 500–2000 Short 
4.5 to 6.5 h
Inactive Urine ≈ 100%
Glibenclamide II 2.5–15 Intermediate  
to long
5 to 7 h
Active
10 h
Bile ≈ 50%
Glimepiride II 1–6 Intermediate
5 to 8 h
Active
3 to 6 h
Urine ≈ 80%
Glipizide II 2.5–20 Short to 
intermediate
2 to 4 h
Inactive Urine ≈ 70%
Gliclazide II 40–320 Intermediate
10 h
Inactive Urine ≈ 65%
Gliquidone II 15–180 Short to 
intermediate
3 to 4 h
Inactive Bile ≈ 95%
*Short duration of activity means < 12 h, intermediate 12–24 h, long over 24 h.
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glibenclamide. SUR1 is a member of the ATP-bind-
ing cassette (ABC) super-family that has two nu-
cleotide binding folds (NBF-1 and NBF-2). Each 
nucleotide binding fold contains the Walker A and 
B motifs and the SGGQ ABC signature, and it is 
important in nucleotide regulation of the func-
tional activities of ABC proteins. SUR1 has three 
transmembrane domains (TMD), TMD0, TMD1 
and TMD2, which consist respectively of 5, 6 and 
6 transmembrane (TM) segments that are numerat-
ed progressively. TMD0 contains the TM segments 
from 1 to 5, TMD1 contains the TM segments from 
6 to 11, and TMD2 contains the TM segments 
from 12 to 17. SUR1 is expressed at higher lev-
els in pancreatic islets. SUR1 is also present in the 
brain. Also a second type of sulfonylureas receptor 
exists; it is named SUR2A (formerly called SUR2), 
and it is an isoform of SUR1. SUR2A is a protein of 
1545 amino acids sharing 68% amino acid iden-
tity with SUR1. SUR2A has a low affinity for glib-
enclamide. Several variants of SUR2A have also 
been identified. One of them, SUR2B, differs from 
SUR2A by 42 amino acids in the C-terminus, where 
it is, instead, similar to SUR1. Although SUR2A is 
expressed predominantly in heart and skeletal 
muscle, SUR2B is expressed widely in other tissues. 
In the past a two-site model (A site and B site) had 
been proposed for the interaction between sulfo-
nylureas, glinides and SUR. The A site is located on 
the eighth (between TM segments 15 and 16) cy-
tosolic loop, which is specific for SUR1. Instead the 
B site involves the third (between TM segments 
5 and 6) cytosolic loop, which is very similar in all 
SURs. According to these different sites of inter-
action, sulfonylureas and glinides can be divided 
into three groups. The first of these includes nate-
glinide, tolbutamide and gliclazide, which are mol-
ecules that bind specifically the A  site of SUR1, 
while the second group, which includes glimepiri-
de and glibenclamide, binds non-specifically the B 
sites of both SUR1 and SUR2A as well as the A site 
of SUR1; finally, the third group (which includes 
meglitinide and repaglinide) binds to the B site of 
SUR1 and SUR2A.
Beside the “first phase”, sulfonylureas also 
increase the “second phase” of insulin secretion 
that begins 10 min later as insulin granules are 
translocated to the membrane of the β-cell. This 
second phase involves the progressive formation 
of new insulin granules, and it is possible only if 
β-cell function is preserved. It is important to un-
derline that the release of insulin induced by sul-
fonylureas is independent of glucose levels, and 
this can increase the risk of hypoglycemia.
Figure 1. Mechanism of action of sulfonylureas
On the top right corner is represented the SUR, while octagon is sulfonylurea (SU). When the SU binds SUR, the flow of K (arrows) 
stopped, so the cell membrane is depolarized. An increased flow of calcium cause the contraction of the filaments of actomyosin 
responsible for the exocytosis of insulin.
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The impairment of the effect on insulin secre-
tion that occurs during chronic administration 
of sulfonylureas is due to the down-regulation 
of the receptor for sulfonylureas on the surface 
of β-cells. This phenomenon disappears after 
discontinuing treatment for a  period of time. In 
fact, resuming the administration of these drugs, 
the first administration effect reappears. Through 
a similar mechanism sulfonylureas can stimulate 
the secretion of somatostatin and suppress the 
secretion of glucagon in δ-cells and α-cells [12, 
13]. In addition to the β-cells of the pancreas, 
sulfonylureas exert their effects on other cells. As 
an example, an increase of receptors for insulin 
present on monocytes, adipocytes and erythro-
cytes has been demonstrated in patients chron-
ically treated with sulfonylureas [14]. Moreover, 
sulfonylureas seem to exert other effects as well: 
they increase peripheral glucose utilization by 
two mechanisms of action, by stimulating hepatic 
gluconeogenesis, and by increasing the number 
and sensitivity of insulin receptors [15]. However, 
their main effect is an increased responsiveness 
of β-cells to both glucose and non-glucose secre-
tagogues (such as amino acids), resulting in more 
insulin released at any blood glucose concentra-
tion. Moreover, and this fact should not be under-
rated, they may cause suppression, sometimes 
significant, of overnight hepatic glucose output, 
thus further lowering the fasting blood glucose 
concentration [16]. 
Extra-pancreatic action of sulfonylureas
Over the years, a  number of interesting ex-
tra-pancreatic actions of sulfonylurea drugs have 
been described. Many of these actions have re-
quired concentrations of sulfonylureas far in ex-
cess of the therapeutic levels usually attained in 
the plasma. 
The extra-pancreatic effects of sulfonylurea 
drugs can be divided into different groups: 
•  Effects probably related to anti-diabetic action: 
enhancement of insulin stimulation of carbohy-
drate transport in skeletal muscle; enhancement 
of insulin action on the liver.
•  Effects possibly related to anti-diabetic action: 
 Direct effects on the liver: inhibition of triglycer-
ide lipase; limitation of anionic substrate move-
ment across the inner membrane of hepatic 
mitochondria; inhibition of ketosis; inhibition of 
glucose output.
 Direct effects on adipose tissue: inhibition of lip-
olysis; inhibition of triglyceride lipase; increased 
uptake and oxidation of glucose. 
•  Effects unlikely related to anti-diabetic action: 
activation of adenylate cyclase; inhibition of ad-
enosine 3’,5’ monophosphate diesterase; inhibi-
tion of catecholamine release in vitro; alteration 
of rate of amino acid incorporation into protein; 
inhibition of transaminase activity; inhibition of 
the ratio of bound to free insulin; reduction of 
intestinal glucose absorption; inhibition in insu-
linases.
•  Effects not related to anti-diabetic action: in-
creased cardiac contractility; effects on water 
balance (either diuretic or anti-diuretic); inhibi-
tion of platelet aggregation [17].
Pharmacokinetics
Although with time and different quantities, all 
sulfonylureas are absorbed by the intestine after 
oral intake, each one with its specific absorption 
time and bioavailability. Hyperglycemia can re-
duce the absorption of sulfonylureas as it impairs 
intestinal motility, thereby reducing the absorp-
tion of all orally administered drugs. This same 
phenomenon occurs for food intake as well. For 
this reason, to optimize their absorption, sulfony-
lureas should be taken 30 min before meals, and 
their dosage should be increased every 2 weeks if 
glycemic control has not been reached. The typical 
starting dose should be low (for example gliben-
clamide 2.5 mg or glimepiride 2 mg). Higher doses 
(for example, more than 10 mg of glibenclamide) 
rarely further improve glycemic control and should 
be avoided [18]. Due to their prolonged biologi-
cal effect, sulfonylureas are given once or twice 
daily. After absorption, sulfonylureas bind almost 
completely to plasma proteins, especially albumin 
(on average 95%, ranging from 90% for chlorpro-
pamide to 99% for glibenclamide). The volume of 
distribution is about 0.2 l/kg.
The biological effect of sulfonylureas often lasts 
much longer than their plasma half-life, because of 
receptor interaction and formation of active me-
tabolites [19, 20], persisting 24 h or more. More-
over, their half-life is prolonged in the presence of 
renal failure. Beside possible alterations of absorp-
tion and metabolism, genetic differences can also 
change the response to sulfonylureas: in recent 
years genetic failure of β-cells has been demon-
strated. These genetic variants obviously alter the 
effectiveness of sulfonylureas. Some of these gene 
polymorphisms were identified in the genes encod-
ing the K+ ATP channel (KCNJ11 and ABCC8). These 
mutations cause a change in insulin secretion and 
insulin response to sulfonylurea treatment. Other 
polymorphisms were found on genes encoding en-
zymes or transcription factors [21].
For all of the above mentioned reasons, sulfo-
nylureas are not all alike: they differ in their dos-
age, rate of absorption, duration of action, route 
of elimination and binding site on their target 
pancreatic β-cell receptor. The pharmacokinetic 
properties, therefore, are the determinant of these 
differences (Table I). 
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As indicated in Table I, it seems worthwhile to 
note that, unlike most of the sulfonylureas char-
acterized by a prevalent renal excretion, gliclazide 
and, above all, gliquidone, show a  predominant 
biliary clearance (= 95%). This can be useful in 
clinical practice, especially when treating diabetic 
patients with renal impairment.
Sulfonylureas lower blood glucose concentra-
tions by about 20% and HbA
1c by 1 to 2% [22]: 
they exert effects on HbA
1c similar to those of 
metformin, but their use entails a greater risk of 
hypoglycemia and of undesired weight gain, aver-
aging approximately 2 kg. 
Side effects
Sulfonylureas are usually well tolerated. The 
most common side effect is hypoglycemia, more 
common with long-acting sulfonylureas such as 
chlorpropamide and glibenclamide [23–25]. How-
ever, all sulfonylureas may cause hypoglycemia, 
usually due to an excessive dosage. It is important 
to remember that hypoglycemia may persist for 
many hours and require in-hospital treatment.
A 4-year retrospective study of 14,000 patients, 
65 years or older, with type 2 diabetes, treated 
with different sulfonylurea drugs, showed that 
episodes of serious hypoglycemia were rare [26]. 
The incidence was higher in those patients tak-
ing glibenclamide, and lower among those tak-
ing tolbutamide  (19.9 vs. 3.5 episodes per 1000 
person-years, respectively). Other shorter-acting 
drugs, such as tolazamide and glipizide, were also 
associated with a  lower incidence, while the in-
cidence with chlorpropamide was similar to that 
with glibenclamide [16]. Patients recently dis-
charged from hospital were at the highest risk 
(4.5 episodes per 100 person-years) [26].
Patients should be cautioned about those sit-
uations in which hypoglycemia is most likely to 
occur: after exercise or a  missed meal, or when 
taking an excessive dosage. In addition to the use 
of longer-acting drugs such as glibenclamide or 
chlorpropamide, it is necessary to recognize other 
situations at risk of hypoglycemia. For example, 
sulfonylureas should be used with caution in pa-
tients who are undernourished or alcohol abusers, 
in patients with impaired renal or cardiac function 
or gastrointestinal disease, in patients concur-
rently treated with salicylates, sulfonamides, fibric 
acid derivatives (such as gemfibrozil), and warfa-
rin [27], and during hospitalization [28]. 
A good way to prevent hypoglycemia is to start 
therapy with sulfonylureas at a low dose. The dos-
age may be increased at intervals of 2–4 weeks 
until the glycemic target is reached. Obviously, 
self-monitoring of blood glucose by the patient 
may be helpful. Nevertheless, in general, patients 
who have managed less fasting hyperglycemia af-
ter a  trial of diet and exercise are more likely to 
develop hypoglycemia.
The reported frequency of sulfonylurea-related 
hypoglycemia in the elderly is variable, and fre-
quently underestimated (usually only severe hy-
poglycemias are considered). Even though this risk 
is lower with the newer sulfonylureas (glipizide, 
glimepiride) [24], these episodes, more frequent 
and dangerous in the elderly, can limit their use. In 
fact, in these patients, autonomic failure, second-
ary to aging and to longer duration of diabetes, 
is responsible for asymptomatic and occult hypo-
glycemias, while difficulty in communication may 
complicate its management. The concept of the 
“frail elderly”, in which the glycated haemoglobin 
(HbA
1c) target was raised up to 8.6%, allows less 
aggressive therapeutic strategies to be followed, 
and does not justify the use of drugs that carry 
a  risk of prolonged hypoglycemia. Thus, old age 
(> 75 years), renal impairment and liver disease 
are conditions in which sulfonylureas should not 
be used as first line therapy, but as second or third 
line agents in type 2 diabetes mellitus. 
Sulfonylureas act directly on β-cells, leading to 
progressive dysfunction and worsening of insulin 
secretion. Thus, despite better glycemic control 
in the short term, diabetes could worsen in the 
long term. The clinical result of this phenomenon 
is known as “secondary failure”, and it represents 
the inevitable fate of all oral hypoglycemic agents, 
especially older sulfonylureas. In fact, patients 
with previous higher dosages and longer treat-
ment with sulfonylureas display a worse response 
to insulin after changing therapy: sulfonylurea 
dosage is independently associated with inade-
quate response to insulin analogues in patients 
with secondary failure [29]. 
Weight gain is an almost constant counterpart 
of treatment with sulfonylureas, even though to 
a lesser degree than that recorded with insulin [30]. 
This certainly constitutes a deleterious effect, es-
pecially in reference to a chronic illness such as di-
abetes mellitus, where the control of body weight 
represents, perhaps, the main target of treatment. 
Fortunately, the weight gain is usually mitigated 
by the concurrent administration of metformin.
Other infrequent side effects that may occur 
with all sulfonylureas include nausea, skin reac-
tions such as erythema multiforme, exfoliative 
dermatitis and also, more rarely, photosensitivity. 
Occasionally, they can cause abnormalities in liver 
function tests, which may rarely lead to cholestat-
ic jaundice, hepatitis and hepatic failure. It seems 
especially important to recall some disturbing side 
effects of chlorpropamide, fortunately no longer 
used, mainly because of its very prolonged du-
ration of action. It may cause, in fact, a flushing 
skin reaction after alcohol ingestion by inhibiting 
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the metabolism of acetaldehyde [31]; it also may 
lead to hyponatremia by increasing the secretion 
of anti-diuretic hormone [32]. This effect has also 
been described with the use of glimepiride and 
glipizide.
Some studies suggest that sulfonylureas may 
affect cardiac function and also may be asso-
ciated with poorer outcomes after myocardial 
infarction [33–35]. An increased mortality from 
cardiovascular disease in diabetic patients tak-
ing tolbutamide was reported in the past decades 
(University Group Diabetes Study) [36]. 
Subsequently, several studies were designed 
to shed light on this alarming association. In the 
Mayo Clinic, in 185 consecutive diabetic patients 
undergoing percutaneous coronary intervention 
after myocardial infarction, the odds ratio for 
death was 2.77 for patients treated with a sulfony-
lurea at the time of the myocardial infarction [37].
In the DIGAMI (Diabetes Mellitus, Insulin Glu-
cose Infusion in Acute Myocardial Infarction) tri-
al, the patients treated with a sulfonylurea at the 
time of myocardial infarction were those with the 
poorest outcome [38]. 
Finally, in a  retrospective Canadian study us-
ing pharmaceutical data for 5795 subjects who 
received initial monotherapy with either a  sul-
fonylurea or metformin, deaths per 1000 per-
son-years during the follow-up period (mean 
4.8 years) were 67.6 for first-generation sulfony-
lurea medications, 61.4 for glibenclamide, and 
39.6 for metformin [39]. The risk of death or of an 
acute ischemic event was greater for subjects ex-
posed to higher amounts of the sulfonylurea, but 
not to metformin [39]. The greatest risk was for 
subjects treated with tolbutamide or chlorpropa-
mide (hazard ratio (HR) 2.1, 95% CI: 1.0–4.7).
An explanation of these results may be found 
in the interaction of sulfonylureas with cardiomy-
ocytes. Indeed, there are sulfonylurea receptor iso-
forms on cardiac myocytes and vascular smooth 
muscle. Insulin secretagogues display different tis-
sue selectivity characteristics at therapeutic con-
centrations, and this may translate into different 
levels of cardiovascular risk [40].
Since ATP-dependent K+ channels are present 
on cardiac cells and coronary vessels, sulfony-
lureas, if present at the time of a myocardial in-
farction, may impair adequate coronary vasodila-
tation, thus resulting in a larger area of myocardial 
damage. Other hypotheses for the effect of sul-
fonylurea medications on cardiovascular events 
and mortality are founded on interference with 
ischemic preconditioning, or possible arrhythmo-
genic effects, and on the inhibitory effect of sul-
fonylureas on the reverse cholesterol transport 
mediated by HDL [41]. 
The treatment with sulfonylureas also carries 
other implications. In fact, there is evidence sug-
gesting that the activation of mitochondrial K+ ATP 
channels plays an important role in the mechani-
cal protection that results from ischemic precon-
ditioning [41]. Glibenclamide prevents cardiopro-
tection induced by ischemia with the interaction 
with mitochondrial K+ ATP channels, whereas gli-
clazide does not. In skeletal muscle, activation of 
K+ ATP channels during fatigue prevents muscle 
dysfunction by reducing resting tension and im-
proving force recovery. However, blocking K+ ATP 
channels of skeletal muscles by glibenclamide 
does not affect the fall in force during fatigue. 
K+ ATP channels can mediate counter-regulatory 
responses to hypoglycemia, at the level of the cen-
tral nervous system [42]. The opening of K+ ATP 
channels during hypoxia also reduces membrane 
excitability and protects neurons from seizure 
activity. It has to be underlined that newer sulfo-
nylureas, such as gliclazide, are selective for the 
pancreatic sulfonylurea receptors over the cardiac 
receptors and do not appear to be associated with 
increased cardiovascular mortality compared with 
metformin or other anti-diabetic medications [43], 
although direct controlled clinical trials have not 
been performed [44, 45]. In a study of 1310 French 
patients with diabetes who were hospitalized for 
myocardial infarction, in-hospital mortality rates 
were significantly lower in patients previously 
treated with sulfonylureas compared with other 
oral medications, insulin, or no medication (3.9%, 
6.4%, 9.4%, and 8.4%, respectively, odds ratio for 
patients receiving sulfonylureas before admission 
compared with no sulfonylureas 0.50, 95% CI: 
0.27–0.94) [44]. Among the sulfonylurea-treated 
patients, mortality was significantly lower in pa-
tients receiving gliclazide or glimepiride  rather 
than glibenclamide, which is not selective for the 
pancreatic sulfonylurea receptors.
In addition to these findings, the results of clin-
ical trials, particularly ADVANCE [46], using newer 
sulfonylureas such as gliclazide, are somewhat 
reassuring, although they were not specifically 
designed to address this issue. Moreover, it has 
been demonstrated that the use of sulfonylureas 
can increase the risk of developing a  neoplastic 
disease [47]. 
Regarding the relation between sulfonylurea 
use and cancer, the evidence is weak: Bowk-
er et al. [47] found that cancer-related mortality 
among residents of the province of Saskatchewan 
in Canada was greater for diabetics treated with 
insulin and sulfonylureas than for metformin us-
ers. However, from this study the relationship be-
tween sulfonylurea use and cancer development 
was inconsistent. In fact, many factors must be 
considered when analyzing the findings from ob-
servational studies that examine the association 
between diabetes therapies and cancer, for exam-
ple sample size of the population examined, type 
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and duration of diabetes, the level of metabolic 
control, comorbidities, and duration of follow-up. 
We know that sulfonylureas are a heterogeneous 
group of drugs, and the effects of single drugs 
are drug-specific rather than class-specific. Look-
ing at the study performed by Monami et al. [48], 
it seems that cancer and its related mortality in 
patients with type 2 diabetes mellitus using glib-
enclamide was significantly higher than in those 
using gliclazide. Furthermore, regarding colorectal 
cancer, there is no evidence that using sulfony-
lureas in type 2 diabetes leads to cancer: rather, 
the risk of developing colorectal cancer in these 
patients is reduced [49]. 
Conclusions
Despite the great number of anti-diabetic 
agents currently available in clinical practice, sul-
fonylureas are still frequently used: maybe this is 
due to their lower cost, to the possibility of mo-
no-dosing and to the presence of an association 
with metformin in the same tablet.
In patients suffering from inadequate glycemic 
control, sulfonylureas can rapidly achieve signif-
icant improvement when added to metformin 
[50–53]. According to recent guidelines, they can 
also be associated with glitazones [54–57], GPL-1 
analogues, DPP-4 inhibitors [58] or long acting in-
sulin when the association with metformin alone 
fails to achieve the glycemic target. Considering 
adverse events, sulfonylureas, especially the older 
ones, are linked to a greater prevalence of hypo-
glycemia, and cardiovascular risk; in this respect, 
newer prolonged-release preparations of sulfony-
lureas are undoubtedly safer, mainly due to reduc-
ing hypoglycemia, and for this reason should be 
preferred.
The European GUIDE study [59], for example, 
compared two sulfonylureas designed for once- 
daily administration used under conditions of ev-
eryday clinical practice. Patients were randomized 
to either gliclazide modified release (MR) 30–120 mg 
daily or glimepiride 1–6 mg daily as monotherapy 
or in combination with their current treatment for 
27 weeks. Even if gliclazide MR and glimepiride 
were similarly effective in improving blood glu-
cose control, gliclazide MR gave approximately 
50% fewer hypoglycemic episodes in comparison 
with glimepiride.
We can conclude that sulfonylureas should be 
used in relatively young patients for a limited peri-
od of time, maybe 3–6 months, in order to rapidly 
achieve adequate glycemic control. In this way we 
can avoid starting insulin, improving the patient’s 
quality of life and his/her compliance and reduc-
ing the cost of anti-diabetic therapy. After 3–6 
months, if adequate glycemic control has not been 
achieved, we should start insulin treatment. On 
the other hand, if we have reached a lower HbA
1c, 
we should replace sulfonylureas with other oral 
anti-diabetic agents, according to the guidelines. 
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